Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Elucidating the genetic variations of Hepatitis B virus implicated in hepatocellular carcinoma biology.
FY 2015-16
Summary
In Canada, over 260 000 people are infected with the hepatitis B virus (HBV) which is transmitted through infected blood or body fluids. Patients infected with HBV have an increased risk of liver disease such as cirrhosis (scarring of the liver) and primary liver cancer (ie., hepatocellular carcinoma, HCC). HCC is the third leading cause of cancer deaths worldwide. HBV infected patients have a higher risk of HCC because the virus can turn on cancer causing genes and disrupt cancer suppressing genes. Further, the HBV can infect cells of the immune system which may impact an individual's immune defense against cancer. The aims of our research are in chronic hepatitis B patients with HCC: (1) Identify whether viral factors believed to be associated with HCC risk (ie., HBV genetic variants, virus insertion into the host genes) occur. (2) Characterize the status of HBV infection in immune cells from these patients. We will utilize a valuable biorespository of clinical samples collected from patients with liver cancer (including patients who underwent liver transplant for cancer). We will analyze blood and liver samples collected using sensitive molecular tests for the presence of the virus in liver and in immune cells for specific viral genetic features with powerful sequencing methods (i.e., deep sequencing). We will compare our findings to a matched group of hepatitis B patients who did not develop liver cancer. There is limited knowledge regarding the genetic characteristics of the HBV that lead to liver cancer in Canadian patients. There is little published data on the characteristics of HBV infection in immune cells of liver cancer patients. This study will generate novel data that will increase our understanding of HBV-related liver cancer biology.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349958
Name
Lau Keith
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the genetic variations of Hepatitis B virus implicated in hepatocellular carcinoma biology.
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Biology; Deep Sequencing; Disease Pathogenesis; Extrahepatic Hbv; Genetic Variants; Hepatitis B Virus; Liver Cancer; Viral Bio-Markers; Viral Hepatitis; Viral Integration
Abstract
In Canada, over 260 000 people are infected with the hepatitis B virus (HBV) which is transmitted through infected blood or body fluids. Patients infected with HBV have an increased risk of liver disease such as cirrhosis (scarring of the liver) and primary liver cancer (ie., hepatocellular carcinoma, HCC). HCC is the third leading cause of cancer deaths worldwide. HBV infected patients have a higher risk of HCC because the virus can turn on cancer causing genes and disrupt cancer suppressing genes. Further, the HBV can infect cells of the immune system which may impact an individual's immune defense against cancer. The aims of our research are in chronic hepatitis B patients with HCC: (1) Identify whether viral factors believed to be associated with HCC risk (ie., HBV genetic variants, virus insertion into the host genes) occur. (2) Characterize the status of HBV infection in immune cells from these patients. We will utilize a valuable biorespository of clinical samples collected from patients with liver cancer (including patients who underwent liver transplant for cancer). We will analyze blood and liver samples collected using sensitive molecular tests for the presence of the virus in liver and in immune cells for specific viral genetic features with powerful sequencing methods (i.e., deep sequencing). We will compare our findings to a matched group of hepatitis B patients who did not develop liver cancer. There is limited knowledge regarding the genetic characteristics of the HBV that lead to liver cancer in Canadian patients. There is little published data on the characteristics of HBV infection in immune cells of liver cancer patients. This study will generate novel data that will increase our understanding of HBV-related liver cancer biology.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lau, Keith
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~